Think Tanks et al

Think Tanks et al

Accessed 7 April 2018

Less than four percent of private investment in health R&D targets the developing world
Liz Sablich
Friday, April 6, 2018
A recent report published by the Brookings Private Sector Global Health R&D Project found that the private sector devotes at least $159.9 billion to investments related to health research and development (R&D) annually. That total includes $156.7 billion from pharmaceutical companies and $3.2 billion from venture capital firms, and encompasses investments focused on both the developed and developing world. But when the researchers further broke out the spending, they found that an exceedingly small share was dedicated to the developing world…

Accessed 7 April 2018

A Ripe Moment for Reducing Vaccine-Preventable Disease 
In her latest commentary, my colleague Nellie Bristol, Global Health Policy Center Senior Fellow, discusses the threat that decreased U.S. foreign assistance will have on the vast strides made in strengthening immunizations systems globally. Over the next several years, three global health activities could result in sustained increases in global vaccination rates and amplify U.S. investments in vaccine promotion mechanisms: immunization surveillance goals outlined in the Global Health Security Agenda; worldwide delivery of the inactivated polio vaccine; and polio transition, which involves the repurposing of polio infrastructure for other health activities. However, an uncertain budget future for these three activities threatens the expansion of this global public good. Nellie provides policy recommendations for the U.S. government that would ensure that the United States remains a leader in global health and pushes forward proven disease prevention interventions that will protect Americans at home and abroad.